Clinical Trials · NCT02489318
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Aragon Pharmaceuticals, Inc.
- Enrollment
- 1,052
- Start date
- Nov 2015
- Locations
- 220 sites, 22 countries
- Primary endpoint
- Radiographic Progression-free Survival (rPFS)